Sigma-Aldrich Reaches New 1-Year High at $102.39 (SIAL)
Sigma-Aldrich (NASDAQ:SIAL) shares reached a new 52-week high during trading on Tuesday , American Banking & Market News reports. The stock traded as high as $102.39 and last traded at $102.21, with a volume of 222,671 shares. The stock had previously closed at $101.48.
A number of research firms have recently commented on SIAL. Analysts at Zacks reiterated a “neutral” rating on shares of Sigma-Aldrich in a research note on Friday, May 9th. They now have a $102.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sigma-Aldrich in a research note on Friday, April 25th. They now have a $95.00 price target on the stock. Finally, analysts at Mizuho raised their price target on shares of Sigma-Aldrich from $85.00 to $95.00 in a research note on Friday, April 25th. They now have a “neutral” rating on the stock. Two research analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $88.63.
The stock has a 50-day moving average of $99.04 and a 200-day moving average of $94.91. The company has a market cap of $12.149 billion and a price-to-earnings ratio of 24.75.
Sigma-Aldrich (NASDAQ:SIAL) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.06 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.03 by $0.03. The company had revenue of $689.00 million for the quarter, compared to the consensus estimate of $690.60 million. During the same quarter last year, the company posted $1.03 earnings per share. Sigma-Aldrich’s revenue was up 2.1% compared to the same quarter last year. Analysts expect that Sigma-Aldrich will post $4.37 EPS for the current fiscal year.
Sigma-Aldrich Corporation is a life science and high technology company. The Company develops, manufactures, purchases and distributes the range of chemicals, biochemicals and equipment available globally and also provides global biopharmaceutical testing services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.